University of Cologne | GenomeWeb

University of Cologne

The partners are working to implement the University of Cologne's QuickNGS software on Bluebee's cloud-based platform

A comprehensive genomic profiling of small cell lung cancer has found that nearly all tumors harbor inactivated TP53 and RB1 genes, along with other genetic mutations.

The test is already being used in the clinic, especially to detect the emergence of resistance in CLL patients following treatment.

NEW YORK (GenomeWeb News) – The Plasmodium vivax parasite species behind most human malaria cases in Asia and Latin America can be traced back to Africa, where some ape species are still frequently afflicted with the parasite, according to a Nature Communications

NEW YORK (GenomeWeb News) – By folding genomic information about patients' lung cancer tumors in with other clinical data to inform treatment choice, patients generally exhibited improved survival, researchers from the

The Institute of Pathology at the University of Cologne in Germany is now offering a lung cancer panel to guide treatment and enroll patients into clinical trials. The center has also been testing Qiagen's newly launched cancer panels for clinical use.

NEW YORK (GenomeWeb News) – A new Nature study suggests that levels of a microRNA called miR-802 rise in response to obesity, leading to the sorts of metabolic changes and insulin resistance features that foretell type 2 diabetes.

Two independent teams have sequenced small-cell lung cancer exomes and transcriptomes, identifying several potential therapeutic leads.

NEW YORK (GenomeWeb News) – Although an aggressive form of lung cancer known as small-cell lung cancer is marked by high mutation rates, it's still possible to detect recurrent alterations affecting a few main pathways and processes in these cancers by bringing together different types of genomic

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.